Waystar Shorts Trim Into Earnings as Call Options Dominate

Short sellers have pulled back from WAY in the days before its earnings report, with short interest falling roughly 5% in a single session on October 26 to 16.1 million shares, or 8.4% of the free float. That remains a meaningful short position, built up steadily over the past month, where SI climbed more than 12%. The week-on-week decline of 3.7% suggests some bears are reducing risk ahead of the print. The borrow market is loose, with availability at 149.9%, meaning there are roughly 1.5 shares available to lend for every one already borrowed. Borrowing costs are low at 0.55%, up about 14% on the week but still well within easy territory. Against that, options traders have shifted notably bullish: the put/call ratio has dropped to 0.53, more than two standard deviations below its 20-day average of 0.59, the most call-heavy reading in months. Shares closed at $28.02 on October 27, down 2.7% on the week, a steeper decline than the roughly flat median move among its closest peers.

The analyst community remains broadly constructive, though with a note of caution. Keybanc raised its target to $35 from $30 on October 16, maintaining Overweight, and the consensus mean target sits around $34, implying roughly 21% upside from the current price. Barclays downgraded to Equal-Weight in mid-September, simultaneously lifting its target from $27 to $30, a move that captures the tension well: the stock has re-rated higher but the easy upside may be narrowing. The bull case centres on Waystar's embedded position in healthcare revenue-cycle management, with more than 30,000 clients, over 5,000 payor connections, and roughly 8.5 billion transactions annually producing high switching costs and net revenue retention in the 108% to 110% range. Bears focus on the 12 to 18 month enterprise sales cycle, the risk that a roughly $34 million tailwind from the 2024 Change Healthcare disruption does not repeat, and the possibility that growth normalises toward mid-single digits as AI-native and EHR-embedded competitors sharpen their offerings.

The ownership register carries one detail worth noting. Advent International holds a 5.8% stake filed under Schedule 13D, meaning it has registered activist intent with the SEC. That is separate from the passive institutional cluster of FMR (10.2% of shares), Canada Pension Plan (9.9%), and BlackRock (9.1%), all of which have trimmed their disclosed stakes over recent filings. The insider picture is less dramatic than the headline numbers suggest. The CEO's October 6 sale of 82,500 shares for roughly $2.2 million was executed under a pre-arranged 10b5-1 plan, as was an identical September transaction; planned sales of this kind carry little informational weight. Net insider activity over the past 90 days, stripping out grants and option exercises, shows net selling of about 247,500 shares, largely a function of those scheduled disposals.

WAY's past two earnings prints produced day-one declines of 4.7% and 13.9% respectively, a track record that likely explains some of the short positioning that has accumulated. The ORTEX short score of 69.5 ranks in the 5th percentile for days-to-cover and reflects that accumulated bearish conviction. The print will test whether the company's retention metrics and AI-driven cross-sell pipeline are translating into the kind of durable top-line expansion that justifies a valuation multiple currently sitting at roughly 11.5 times EV/EBITDA, as well as whether the shift in options positioning toward calls reflects genuine confidence or simply a tactical squeeze ahead of results.